PH-762
Nucleic Acid Target: PD-1
Phio Pharmaceuticals
Most recent annual filing: 2026-03-15
- PH-762 corporate update2026PH-762 corporate update, 2026, routine
- PH-762 filing3Q 2026PH-762 filing, 3Q 2026, major
- PH-762 manufacturing update2H 2026PH-762 manufacturing update, 2H 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
PH-894
Nucleic Acid Target: BRD4
- Undisclosed indication
Technology platforms
INTASYL
Proprietary self-delivering small interfering RNA (siRNA) gene silencing platform. Chemically modified siRNAs with spontaneous cellular uptake — no formulations, nanoparticles, or electroporation required. Targets a broad range of cell types and tissues; designed for immuno-oncology applications including direct-to-tumor injection and adoptive cell therapy (ACT). Demonstrated preclinical activity against PD-1, BRD4, CTLA-4, TIGIT, and CTGF.
Targets: PD-1, BRD4, CTLA-4, TIGIT, CTGF
Biotech Distilled coverage (3)
- 2026-08-07 UPDATE: Phio Pharmaceuticals (PHIO) - The FDA Meeting That Keeps Moving 🔒 Paid
- 2026-05-08 UPDATE: Phio Pharmaceuticals (PHIO) - The ORR Keeps Shrinking 🔒 Paid
- 2026-04-15 Phio Pharmaceuticals (PHIO) - Scientific Deep Dive for PH-762 and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.